Dexmedetomidine Sublingual — Competitive Intelligence Brief

Dexmedetomidine Sublingual (Dexmedetomidine Sublingual) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Neurology.

phase 2 Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Neurology Small molecule

Target snapshot

Dexmedetomidine Sublingual (Dexmedetomidine Sublingual) — NYU Langone Health. Alpha-2 adrenergic receptor agonist

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexmedetomidine Sublingual TARGET	Dexmedetomidine Sublingual	NYU Langone Health	phase 2	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Clonidine Oral Liquid Product	Clonidine Oral Liquid Product	Region Örebro County	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Combigan Ophthalmic Solutiom	Combigan Ophthalmic Solutiom	Genovate Biotechnology Co., Ltd.,	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist	Alpha-2 adrenergic receptors and beta-adrenergic receptors
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
dexmedetomidine 1 µg/kg IV	dexmedetomidine 1 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Intravenous dexmedetomidine	Intravenous dexmedetomidine	University of Jordan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Fexofenadine HCL and pseudoephedrine HCL	Fexofenadine HCL and pseudoephedrine HCL	Sanofi	marketed	Antihistamine and decongestant combination	H1 receptor (fexofenadine); alpha-1 and alpha-2 adrenergic receptors (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

1. Allergan · 3 drugs in this class
2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
3. National Cancer Institute, Egypt · 2 drugs in this class
4. The University of Hong Kong · 2 drugs in this class
5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
6. Fayoum University Hospital · 1 drug in this class
7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
10. KAT General Hospital · 1 drug in this class